Table 4.
Lead author | Yr | Number of patients | Location of tumor thrombus | Treatment | Operative mortality rate (%) | 5-Year survival rate (%) | Median survival time (mo) |
Kumada K et al[54] | 1990 | 13 | Vp4 | Hx. | - | - | - |
Yamaoka Y et al[55] | 1992 | 29 | Vp3, 4 | Hx. | 11 | (11.6:3YSR) | - |
Ikai I et al[56] | 1998 | 29 | Vp4 | Hx. | - | 4 | - |
29 | Vp3 | Hx. | - | 11 | - | ||
Ohkubo T et al[57] | 2000 | 47 | Vp2, 3, 4 | Hx. | 0 | 23.9 | 14 |
Wu CC et al[58] | 2000 | 15 | Vp4 | Hx. | 0 | 26.4 | - |
97 | Vp1, 2, 3 | Hx. | 3.1 | 28.5 | - | ||
Minagawa M et al[59] | 2001 | 18 | Vp2, 3, 4 | TACE → Hx. | 0 | 42 | 31 |
Fukuda S et al[60] | 2002 | 19 | Vp3, 4, | Hx. → HAI etc. | 0 | 36.3 | 22.1 |
Vv2, 3, B3, 4 | |||||||
Poon RT et al[61] | 2003 | 20 | Vp3, 4, | Hx. | 5.7 | 13.3 | 6 |
Vv2 | |||||||
Lau WY et al[62] | 2004 | 7 | Vp4 | PIAF→Hx. or Yttrium 90 ia + doxorubicin iv → Hx. | 4.1 | 56 | a |
Pawlik TM et al[63] | 2005 | 102 | Vp3, Vv2, 3 | Hx. | 5.9 | 10 | 11 |
Ikai I et al[64] | 2006 | 78 | Vp3, Vp4 | Hx. | 3.8 | 10.9 | 8.9 |
Le Treut YP et al[65] | 2006 | 26 | Vp3, 4, Vv2, 3 | Hx. | 11.5 | 13 | 9 |
Zhou J et al[66] | 2006 | 381 | Vp2, 3, 4 | Hx. | - | 12 | - |
Survival curves remain above a survival rate of 50%. PIAF: Doxorubicin, CDDP, 5-FU iv + Interferon-α sc; Hx.: Hepatic resection; HAI: Hepatic arterial infusion chemotherapy; Vv2: The main trunk of hepatic vein; Vv3: The inferior vena cava; B3: 1st order branches of bile duct; B4: The common hepatic duct; YSR: Year survival rate.